Teva Pharmaceutical Industries has agreed to acquire MicroDose Therapeutx and its proprietary inhalation technologies for US$40 M upfront and up to US$125 M in post-acquisition milestones. MicroDose’s pipeline of products for lung diseases and infections is led by MDT-637, an inhalable small molecule fusion inhibitor that prevents replication of the respiratory syncytial virus and which is expected to begin Phase II trials later in 2013. The deal complements Teva’s therapeutic focus on respiratory and CNS diseases as part of a revised growth strategy outlined in December 2012.